(Alliance News) - Diurnal Group PLC on Wednesday announced a positive outcome in the trial of a treatment for a hormone deficiency.
The pharmaceutical company said during the phase one proof-of-concept clinical trial, its oral testosterone formulation DITEST delivered positive headline results.
The study looked at the pharmacokinetics, safety, and tolerability of DITEST in 24 adult men with primary or secondary hypogonadism, a condition resulting in testosterone insufficiency.
The trial found oral administration of DITEST achieved testosterone levels within the healthy young male adult range.
Also, the company said there was no impact on the extent of absorption of testosterone from DITEST taken with meal or in the fasted state, as opposed to currently available testosterone treatment undecanoate, which requires a high-fat meal.
Martin Whitaker, chief executive, said: "We are excited by the potential of DITEST to address a significant unmet patient need for hypogonadal men, which affects over 60 million men globally".
"We look forward to engaging with regulators in the US and Europe to progress DITEST to late stage clinical trials, and to discussing these positive trial data with potential development and commercialization partners," Whitaker said.
Diurnal shares were up 4.9% in London at 32.00 pence each on Wednesday.
By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
